Business Context and Reporting Period
Company: Bioanalytical Systems, Inc. (Note: Input metadata listed "Inotiv, Inc.", but the filing text identifies the registrant as Bioanalytical Systems, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: December 31, 2010
Business Overview: The Company provides contract laboratory research services (bioanalytical analysis, toxicology) and manufactures scientific instruments (liquid chromatography, electrochemical monitoring) for pharmaceutical, biotechnology, and academic clients. Operations are divided into two segments: Research Services and Research Products.
Key Financial Metrics
| Metric | Q1 2011 (Dec 31, 2010) | Q1 2010 (Dec 31, 2009) |
|---|---|---|
| Total Revenue | $8,090 | $6,377 |
| Gross Profit | $2,716 | $1,196 |
| Gross Margin | 33.6% | 18.8% |
| Operating Income | $538 | $(1,247) |
| Net Income | $310 | $(1,488) |
| Diluted EPS | $0.06 | $(0.30) |
| Cash from Operations | $737 | $242 |
| Cash & Equivalents (End of Period) | $1,238 | $524 |
| Total Debt (Current + Long-term) | $9,561 | N/A |
Note: All figures in thousands except per share data.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 26.9% year-over-year, driven by a 27.7% increase in Service revenue and a 24.3% increase in Product revenue.
- Profitability Turnaround: The Company returned to profitability, reporting a net income of $310 compared to a net loss of $1,488 in the prior year. Operating income improved from a loss of $1,247 to a profit of $538.
- Margin Expansion: Gross margin improved significantly to 33.6% from 18.8%, attributed to higher revenue absorption of fixed costs and cost containment measures.
- Expense Reduction: Total operating expenses decreased 10.9% to $2,178, primarily due to a workforce reduction in January 2010 and reduced marketing and R&D spending.
- Segment Performance:
- Services: Bioanalytical analysis revenue rose 44.4% and Toxicology revenue rose 25.0%.
- Products: Sales of Culex automated in vivo sampling systems increased 54.2%.
Guidance, Outlook, and Risks
- Outlook: Management expects slow but continued improvement in new bookings for fiscal 2011, with little improvement in pricing. Gross profit margins are expected to improve due to ongoing cost controls.
- Liquidity: The Company projects sufficient liquidity to meet fiscal 2011 operations and debt obligations based on current cash, operating cash flow, and available credit line capacity ($2,120 available on a $3,000 line).
- Debt Covenants: The Company is currently in compliance with financial covenants (fixed charge coverage and tangible net worth). However, management notes that if operations materially fail to meet expectations, they may require waivers from lenders.
- Internal Controls: Two material weaknesses identified in the prior fiscal year (income tax accounting and debt covenant monitoring) have been corrected as of December 31, 2010. Disclosure controls and procedures were deemed effective.
- Risks: Key risks include dependence on the pharmaceutical industry's R&D spending, pricing pressure in the CRO market, and the potential need for loan modifications if financial targets are not met.
Investor Verification Checklist
- Debt Maturity & Covenants: Verify the status of the $500 principal payment due to Regions Bank in February 2011 and ongoing compliance with the tangible net worth covenant ($8,500 minimum).
- Revenue Quality: Assess the sustainability of the 26.9% revenue growth given management's expectation of "little improvement in pricing."
- Capital Expenditures: Review the $311 capital expenditure for the quarter, specifically the mandated waste-water treatment facility, to ensure it does not strain liquidity.
- Customer Concentration: Evaluate reliance on a small number of pharmaceutical and biotech clients, as noted in the business description.
- Internal Control Remediation: Confirm that the monthly review of debt covenants and tax accounting procedures remain effective in subsequent periods.